This study was performed to systematically assess the prevalence, topography and prognostic impact of disseminated tumor cells (DTCs) in lymph nodes (LN) of patients with primary, regional and distant metastasis-free head and neck squamous cell carcinoma (HNSCC) who underwent resection with elective neck dissection. From the routinely processed resection specimen, we could prospectively analyze a total of 1.137 exactly mapped LNs of 50 pN0-HNSCC patients, classified as tumor free by routine histopathology. Three immunohistochemistry (IHC) assays using antibodies directed against CK5/14, a broad spectrum of CKs (1-8, 10, 14-16 and 19), and CD44v6, respectively, were applied on 4.190 LN sections to detect DTCs. The IHC results were correlated with clinicopathologic parameters and clinical follow-up data. We detected seven micrometastases (MM) in five patients and 31 DTCs in 12 patients. Overall, 15 (30%) patients were positive for DTCs or MMs. Strikingly, the anatomical distribution of LN affected with DTCs was not random, but was dependent on the lateralization of the primary tumor and clustered significantly most proximal to the primary tumor. None of the investigated patients developed loco-regional lymphatic or distant metastasis during the mean follow-up period of 71 months. Our results reveal clinically occult tumor cell dissemination as an early and frequent event in HNSCC. Considering that higher rates of recurrences in therapeutic LN dissection concepts have been reported than in elective neck dissection strategies, our DTC-data support to perform elective neck dissections, since they appear to be effective in preventing loco-regional lymphatic recurrence from LN DTCs or MMs.
This study was performed to systematically assess the prevalence, topography and prognostic impact of disseminated tumor cells (DTCs) in lymph nodes (LN) of patients with primary, regional and distant metastasis-free head and neck squamous cell carcinoma (HNSCC) who underwent resection with elective neck dissection. From the routinely processed resection specimen, we could prospectively analyze a total of 1.137 exactly mapped LNs of 50 pN0-HNSCC patients, classified as tumor free by routine histopathology. Three immunohistochemistry (IHC) assays using antibodies directed against CK5/14, a broad spectrum of CKs (1-8, 10, 14-16 and 19) , and CD44v6, respectively, were applied on 4.190 LN sections to detect DTCs. The IHC results were correlated with clinicopathologic parameters and clinical follow-up data. We detected seven micrometastases (MM) in five patients and 31 DTCs in 12 patients. Overall, 15 (30%) patients were positive for DTCs or MMs. Strikingly, the anatomical distribution of LN affected with DTCs was not random, but was dependent on the lateralization of the primary tumor and clustered significantly most proximal to the primary tumor. None of the investigated patients developed loco-regional lymphatic or distant metastasis during the mean follow-up period of 71 months. Our results reveal clinically occult tumor cell dissemination as an early and frequent event in HNSCC. Considering that higher rates of recurrences in therapeutic LN dissection concepts have been reported than in elective neck dissection strategies, our DTC-data support to perform elective neck dissections, since they appear to be effective in preventing loco-regional lymphatic recurrence from LN DTCs or MMs.
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with a short-term lethal outcome in all untreated cases. Despite major surgical innovations and better reconstructive techniques allowing for more radical tumor resections as well as progress in adjuvant treatment modalities, overall survival (OS) rates have not improved considerably over the past decades. 1 However, patients with early stage HNSCC, who are free from lymph node (LN) or distant metastases (DMs) at initial presentation, may be cured by surgical resection alone with a 5-year survival rate of over 80%. 2, 3 Therefore, current guidelines do not recommend adjuvant therapy for UICC (Union for International Cancer Control) stage I and II-patients. 4 Yet, around 20-30% of these early stage HNSCC-patients develop locoregional relapse and/or DMs, 5 indicating clinically occult early tumor cell dissemination. In this context, it is notable that with modern multimodal therapies resulting in improved local control, the development of DM after successful primary tumor resection recently became more relevant for limiting the survival of HNSCC patients. 6 The presence, the number, and the extracapsular extension of regional LN metastases are the most relevant prognostic factors for patients with HNSCC and can indicate systemic progression. If a single ipsilateral LN metastasis is present (N1), the survival rate decreases to only around 50%. 7 In cases of bi-or just contralateral metastases (N2c), survival is further reduced by another 50% and systemic therapy is strongly recommended for these patients. 8 Therefore, current clinical guidelines recommend prophylactic systematic cervical LN dissection, even in clinically LN negative patients. 9 Such a selective neck dissection procedure should collect at least six LNs. 4 In light of the existing clinical data, it appears therefore paramount to precisely determine lymphatic spread. However, current clinical imaging methods enabling a spatial resolution down to few millimeters fail to reliably diagnose LN involvement, since 20-40% of patients with negative findings (cN0) display metastases upon routine pathological analysis. 10 But even routine histopathology does not detect minimal tumor cell spread effectively. For example, isolated disseminated tumor cells (DTCs), which are regarded as potential metastatic precursor cells, 11 19, 20 To obtain systematic data on LN-DTC and their relevance in HNSCC, we prospectively analyzed the prevalence, anatomical distribution and clinical significance in a defined cohort of HNSCC-patients with tumors of the lips, the oral cavity, parotid glands and paranasal sinuses, who underwent surgical resection with extensive bilateral selective neck dissection and who were classified as node negative upon routine histopathology (UICC stages I, II, III and IVA). To increase DTC detection probability, we investigated three consecutive slides per LN on which we performed three immunohistochemical assays (IHCs). We used antibodies directed against CK5/14, which are predominantly expressed in the basal layer of the oral stratified squamous epithelium 19 and abundantly expressed by well and poorly differentiated HNSCC, 21 with a pan-cytokeratin antibody (AE1/AE3), which was most commonly used by previous comparable studies, 8, 22 and finally with an antibody against CD44v6, which is abundantly expressed by HNSCC cells but not by lymphocytes.
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Patients and Methods
We prospectively collected all available FFPE-material from LNs of patients with primary UICC stage I, II, III and IVA HNSCC who were treated surgically at our institution between September 2006 and January 2011. The study protocol had been reviewed and approved by the local ethics committee (# 3090). All patients gave written consent for the sampling of the LNs and their investigation regarding the presence of DTCs. All patients underwent radical tumor resection including selective LN dissection and plastic reconstruction by means of local or regional pedicled flaps or by free tissue transfer. Inclusion criteria for the study were newly diagnosed clinically node-and metastasis-negative HNSCC (cN0, cM0), surgical therapy for the primary site with curative intent and elective neck dissection with or without adjuvant therapy and pN-category 5 0. Histological examination of the selective neck dissection specimen had to include at least six LNs.
Exclusion criteria were histological diagnosis other than squamous cell carcinoma (SCC), distant metastasis at initial presentation, pN-and pM-status other than 0, primary treatment outside our department and previous malignancy in the head and neck area. Altogether, 50 of 113 patients met the inclusion criteria. The median observation period was 71 (range 0-122) months.
Eleven LNs from four non-cancer patients with lower jaw osteomyelitis (n 5 2) or mandibular fractures (n 5 2) were excised, processed as described above and used as negative controls.
Clinical staging
Clinical staging of patients with HNSCC included clinical examination, a panoramic radiograph of the jaws, a contrast enhanced computerized tomography (CT) of the head and neck region, chest X-ray (CXR) 6 CT of the thorax, an ultrasound examination of the neck LNs, an abdominal ultrasound examination, and a panendoscopy under general anesthesia including an incisional biopsy of the lesion.
Ultrasound examination of neck LNs
The superficial position of the locoregional LNs allows for a precise mapping of the LNs according to the American Academy of Otolaryngology -Head and Neck Surgery (AAHNS)-classification; the LNs can be precisely located during neck dissection and a correlation with histopathological findings can be established. 24 This classification defines preferred target-regions of LN-metastases from SCCs of the upper aerodigestive tract. Based on anatomical landmarks, like the stylohyoid muscle or the cricoid cartilage, six partially subdivided levels (IA, IB, IIA, IIB, III, IV, VA, VB and VI) are defined. It is uniformly used by radiologists to accurately localize nodal lesions within the defined levels of the neck 25 as well as by surgeons in order to define the specific contents of neck levels removed during selective neck dissection procedures and finally by pathologists to report on the precise location of detected LN-metastases upon histopathological examination. 26 Ultrasound of the neck soft tissues was performed on the eve of surgery as described earlier. 27 Findings of the ultrasound examination were depicted in a diagram of the neck LNs comprising levels I through VI according to Som et al. 28 (Supporting Information Figures S1-S   3 ). The map was later used to catalogue the LNs, which were excised during the neck dissection.
Treatment of the patients
Patients were treated according to the recommendations of the institutional multidisciplinary head and neck tumor board in concordance with the national S3-guideline for the treatment of oral cavity carcinoma. 4 Surgical tumor therapy comprised of: (i) excision of the primary tumor with a target of 1,5 cm of surrounding clinically uninvolved tissue to obtain clear margins; (ii) selective neck dissection (most often comprising levels I-IV); and (iii) immediate reconstruction of the resulting bony defects by alloplastic reconstruction and of the soft tissue defects by primary wound closure, regional flaps or free tissue transfer, respectively. Neck dissection was performed bilaterally if (i) tumors were located in the floor of the mouth (C04) or tongue (C02); or (ii) if closer than 9 mm to the midline in the lips (C00), alveolus and gingiva (C03, C04) or palate (C05). Unilaterally, neck dissection was performed for tumors of the buccal mucosa (C06), parotid gland (C07) and maxillary sinus (C31). Adjuvant therapy was eventually recommended upon consultation of the interdisciplinary head and neck tumor board regarding the definitive pathological TNM-status and the overall performance of the patient. Usually, adjuvant therapy was advised if (i) margins were not clear or closely reached by the tumor ( 3 mm), (ii) the tumor had a T-category 3, (iii) the tumor was poorly differentiated (G3), (iv) lymphangio-(L1) or vascular invasion (V1) was present, or (v) perineural spread (Pn1) had taken place.
Preparation and histopathological assessment of the dissected LNs
The neck dissection specimens were processed in the operating theatre in order to retrieve the LNs identified in the ultrasound examination and depicted on the diagrammatic LN map elaborated upon the ultrasound examination preoperatively (see above). They were processed in the operating theatre shortly after dissection, fixed in 4% phosphate-buffered formaldehyde, assigned with numbers, and individually sent for routine histopathological examination. The remaining neck dissection tissue was separated according to the AAHNS-neck levels (I-VII) and submitted for histopathological assessment. 24 For routine histopathological analysis, single nodes were cut into halves if >5 mm in maximum diameter, and embedded in paraffin as a whole if 5 mm or less in maximum diameter. Neck dissection specimens were screened for the presence of LNs and the retrieved nodes were likewise embedded as a whole if <5 mm and bisected if larger than 5 mm in maximum diameter. Of these embedded (half) nodes, two consecutive transections were stained with hematoxylin and eosin and assessed for the presence of metastases.
Immunohistochemistry
All available FFPE-primary tumor specimens (PT) and LN preparations in stock from the patients were included in the study. Four consecutive paraffin sections measuring 4 mm in thickness were taken from the planar cut surface of the block comprising the maximum diameter of the LNs and placed on positively charged HistoBond V R adhesive microscope slides (Marienfeld, Lauda-K€ onigshofen, Germany). Slides were incubated for 30 min at 1008C and overnight at 608C. Then, the slides were dewaxed 23 for 10 min in xylene and rehydrated in descending ethanol concentrations ranging from 99,5-70% for 5 min each. Antigen retrieval was done at 958C in 13 EDTA (Ethylenediaminetetraacetic acid)-buffer for 30 min. After inactivation of endogenous peroxidase with 0,3% H 2 O 2 -PBS for 10 min sections were treated using the Vectastain ABC kit (Vector V R Laboratories, Burlingame, CA), according to the manufacturer's protocol in an automated immunostaining system (i6000, BioGenex V R , Fremont CA). Nonspecific binding was prevented by incubation with normal serum for 20 min at room temperature (RT), followed by incubation with the primary antibodies for 30 min at RT. These were a cocktail of rabbit 0 -diaminobenzidine-chromogen-subtrate (DAB 1 Chromogen, DAKO V R , Carpinteria, CA) for 10 min at RT. Finally, slides were counterstained with haematoxylin-eosin, dehydrated and coverslipped with a mounting automat (Sakura GLC 550, Tissue-Tek V R , Alphen aan den Rijn, The Netherlands). Negative controls included omission of the primary antibodies for the tumor specimens, and staining of healthy LNs derived from patients without evidence of HNSCC, which had been excised for other reasons. The PTtissue was assessed by the immunoreactive score (IRS) originally described for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. The IRS is obtained by multiplying the percentage of positive cells (class I: <10%, class II: 11-50%, class III: 51-80 and class IV: >80% positive cells, respectively) with the mean staining intensity (class I: weak, class II: moderate and class III: strong). Thus, multiplying the score values, an IRS scale ranging from 1 to 12 was obtained. 29 The LNsections were completely screened by A.K.F. at a magnification of 203 and all suspected micrometastases (MMs), tumor cell clusters, ITCs 14 or ambiguous findings were selected and reviewed in a blinded fashion by two experienced pathologists (S.B. and C.T.). In addition to marker-positivity the following morphological parameters to determine DTCs were applied: increased size and irregular shape of the nuclei (20 mm), prominent nucleoli and scarce cytoplasm, which was irregularly (pronounced intense or pale) stained. 30 CK-positivity had to pertain to the cytoplasm as well as to the membrane in order to be able to differentiate a supposed tumor cell from phagozytotic cells. Discordant findings were reevaluated and finally diagnosed in a consensus decision by the two pathologists.
In depth-analysis by step sectioning of selected LNs of representative patients To test, whether our findings might represent proverbially the tip of an iceberg, we selected 7-8 LN from different levels ipsi-and contralaterally from two patients without findings upon the primary investigation (#32 and 34) and from one patient with detected MMs and DTCs (#2) to generate a substantially higher amount of sections per LN. Doing so, we processed the LN by step serial sectioning according to the protocol applied for sentinel lymph nodes (SLN) from SCCs of the head and neck: of the trimmed slides 4 consecutive sections of 2-3 mm were mounted on slides, separately numbered from 1 to 4. Then, 60 mm were discarded, and the next four sections (5-8) were taken. This procedure was repeated through the entire block until 24 sections of each LN were obtained. All number 1, 5, 9, 13, 17 and 21 sections were H&E-stained, all number 2, 6, 10, 14, 18 and 22 sections of a LN were processed by pan-cytokeratin (AE1/AE3) immunohistochemistry. 31 Altogether, we obtained 138 additional slides for H&E-staining and a further 138 slides for pan-cytokeratinstaining from 23 representative LN of 3 patients (5 with MMs or DTCs and 18 without findings). In case of MM detected by these in depth-analyses, we performed CK5/14-and CD44v6-immunohistochemistry also on the consecutive two slides.
Patient follow-up
After discharge, patients were routinely controlled in our out-patient clinic (monthly visits in the first year, bimonthly in the second, trimonthly in the third and so on for six years and once a year afterwards. Aftercare included a clinical examination, a contrast enhanced CT of the head and neck performed three months after completion of the surgical or eventual adjuvant therapy (T 0 -CT), two times per year in the first two years, and once per year between the third and fifth years. Follow-up for this study was at least 5 years and no patient was lost to follow-up.
Statistical analysis
All statistical calculations have been executed in R. 32 The exact binomial test was used to detect the statistical significance of deviations from the theoretically expected distribution of positive findings (metastases, MMs and DTCs) into the two halves of the neck ipsi-or contralaterally in relation to the center of the PT.
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Survival analysis procedures were performed by using the R-package survival. 34 Tests for equal hazards were done by using the coxph function, which fits a Cox proportional hazards model. 
Results
Prevalence of LN-DTCs in pN0 HNSCC
In the first step, we validated the use of our selected markers/antibodies for DTC detection. Ideally, the used markers are commonly and strongly expressed in tumor tissues of the investigated tumor entity and not detectable in lymphatic tissue. To validate this prior to DTC detection, we tested the staining performance for each of the three different antibodies (CK5/14; AE1/AE3; CD44v6) in matched PT tissues (n 5 150) of the 50 investigated cases, which revealed marker expression in all tumors ( The same lesions. 2 The reevaluation of the missing two IHC-assays (CK5/14 and CD44v6 in pts. #29 and #57 and AE1/AE3 and CD44v6 in pt. #43, respectively) showed that these MMs were only detectable in the single reported positive sections.
revealed overall 15 pN0-staged patients (30%) as positive for MMs or single DTCs. For DTC-detection performed in > 1000 LNs, as in the present study, sentinel LN workup (i.e., sectioning and staining of the whole LN) is clearly not feasible. However, to test whether our data were representative, we selected three cases (pts. #2, #32 and #34) in which we sectioned representative LNs from different levels ipsi-and contralaterally (n 5 7-8) completely and stained six slides with H&E and six applying the IHC with the AE1/AE3. While no MMs and DTCs were found in two cases initially scored as DTC/MM negative (pts. #32 and #34), we detected additional MMs/DTCs in the patient initially already positive for MMs/DTC (pt. #2, Supporting Information Table S2 and Fig. S3 ). This experiment also validated the stained cell clusters >200 mm as MMs and did not reveal any hidden established LN metastasis. Subsequent IHCs with antibodies against CK5/14 and CD44v6 disclosed MMs as positive in all three IHC (Figs. 1eh) , Supporting Information Table S2 ).
Topography of LN-DTC and MMs in pN0 HNSCC
To get further confirmation that the IHC-identified individual DTCs are indeed related to HNSCC, we hypothesized that their topographical distribution would not be random, but follow a distribution pattern expected from established metastases (i.e., initial involvement of LNs most proximal to the primary tumor, followed by ipsilateral distribution with increasing distance to the primary tumor, and eventually contralateral involvement. 37 For testing this, all resected LNs were precisely mapped and assigned to zones (level IA-VB) according to the American Head and Neck Society (AHNS) mapping scheme (Fig. 2, Supporting Information Fig. S1 and S 3 ). 38 A first evaluation revealed that isolated DTCs were significantly more frequently located within the three levels most proximate to the primary tumor (level IB through III; p 5 0,0008; two-sided binomial test; Table 1 and Fig. 2) . Notably, not all levels were affected, since we did not detect any involvement of the contralateral levels III-VB and ipsilateral levels IV-VB (Fig. 2) .
Next, we tested whether the lateralization of MM and DTCs was dependent on the lateral position of the primary tumor. We performed the exact binomial test with the null hypothesis that the distribution of the lesions was by pure chance. In fact, this evaluation revealed that of eight rightsided tumors seven (87,5%) had ipsilateral LN involvement while only one case (12,5%) had a MM on the contralateral side. 
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). Notably, the two cases with contralateral findings showed also ipsilateral DTCs/MMs. Hence, the observed mode of DTC spread to regional LNs was mainly according to the routes described for established metastasis of HNSCC for the regions of the oral cavity, oropharynx and paranasal sinuses. 37, 39 For instance, in case of an oral cavity tumor, these routes start at level IB and continue through levels IIA and III to end up at level IV and eventually VB. 40 Finally, we checked whether an anatomical level or levels between the primary tumor site and the location of the LN-DTC were skipped, since skipping of sub-anatomical levels by lymphatic metastasis can potentially occur in HNSCC. 41 No skipping of lymphatic stations was observed in 10 (66%), whereas it was found in 5 patients (33%; one level was omitted in four and two consecutive levels in one patient; Table 1 ). The number of skipped levels was Poisson-distributed with k 5 0,4 (95% confidence interval for k 5 0,4: 0,08-0,72).
Correlation of clinicopathological data with the detection of LN-DTCs and MMs
The topographical distribution of the rare DTCs and MMs, reflecting the topography of established HNSCC metastases, indicated that these cells are indeed tumor-related. To test their clinical relevance, we correlated their presence first with clinicopathological parameters, but could not observe any statistical significant association (Table 2) . Then we correlated their presence with the median follow-up period of 71 months (range 0-122) to determine their potential impact on disease free survival (DFS) and OS. However, we did not observe a statistical significant association of DTC/MM detection and DFS or OS (Fig. 3) .
Patients with LN-DTCs/MM had only a minimal shorter median DFS compared to patients without any LN involvement (54 vs. 57 months) whereas we detected no differences in median OS (71 months for both groups).
Discussion
The data from our present study revealed that LN-DTCs are present in at least 30% of pN0 HNSCC patients, indicating that significant tumor cell dissemination occurs earlier than previously thought in this tumor entity. 42 Since the surgical procedure performed in our patient cohort included a selective bilateral neck dissection, most often comprising levels I-IV, we were able to investigate with our IHC-detection assay a substantial number of LNs (n 5 1.137) diagnosed as Localization of tumor, n (%)
C03 (alveolus and gingiva) 0 (0%) 2 (17%) 2 (13%) 9 (26%) C04 (floor of mouth) tumor free by routine histopathology. To increase the chance detecting DTCs/MMs, we performed three IHC on consecutive slides, cut in a distance of 5-30 mm from the original cut-surface of the histopathologic examination. In the first IHC, we applied an antibody cocktail against CKs 5 and 14 as epithelial markers, because they are predominantly expressed by HNSCC. 20 A second IHC was performed on a consecutive slide with the pan-CK antibody AE1/AE3, widely used in LN MM detection studies, including those in HNSCC (Table 3) . AE1/AE3 covers besides CKs 5/14 additionally 4 Fisher's exact test. 5 The pTNM-stage matches the clinical UICC-stage since only pN0-tumors were included in the study. 6 We decided to take the number of excised LNs into account instead of the nomenclature of operative procedures like selective neck dissection or radical neck dissection since we believe that it is a better measure of the extent of LN dissection than the former. 23 The differences we observed in DTC frequencies among the three different IHCs (Table 1) can be explained by the fact that we performed the CK5/14 IHC on the first section. The remaining IHCs, which were made on the following consecutive sections, did not contain any further material of isolated DTCs from the first slide. The larger MMs available also on consecutive slides (except for the three MMs in pts. #29, 43 and 57, s. Table 1) , displayed expression of all investigated markers (Table 1 and  Supporting Information Table S2 for the in-depth analyses) suggesting no relevant downregulation of these epithelial markers, at least at the stage of MM.
Clearly, our DTC-detection approach might have failed at detecting DTCs/MMs located below sections cut from the FFPE block. To address this issue, we selected three patients from our cohort (two DTC/MM-positive and two DTC-negative) for complete sectioning of the remaining LN FFPE tissue, similar to SLN processing. This experiment suggested that our IHC-approach did not miss significant numbers of DTCs/MMs, since no additional DTCs were found in cases determined as DTC/MM-negative in the initial IHC screening. In addition, no established metastases were observed in LNs initially diagnosed as positive just for DTCs/MMs. However, in MM/DTC-positive cases, the number of MMs and DTCs per patient might have been underestimated by our approach, since additional MMs and DTCs were detected in LNs of initially DTC/MM positive cases (Supporting Information Table S2 and Fig. S3 ). If we consider the 30% DTCpositive patients and realize that we just investigated material obtained from selective neck dissection procedures (mostly comprising AAHNS-levels I through IV resulting in 23 available LNs per patient on average) and that we only stained three or six cross sections of each LN accounting for 3-6/ 2000th of the LN volume, 44 it will be easy to imagine that even our comprehensive data set may just allow a glimpse on the true content of DTCs and MMs. Nevertheless, we consider our IHC data from the reevaluation of > 4.000 LN sections from 50 pN0 HNSCC patients as representative. We detected in 10% of the patients MMs that were missed by routine histopathology and would lead to an upstage from pN0 to pN1(mi) or pN2c(mi) respectively. This number is very similar to previous studies in HNSCC, independent of the IHC assay used and although substantially smaller numbers of LN sections were screened (Table 3) .
Interestingly, only two studies in pN0 HNSCC (both on SLNs) distinguished between DTCs and MMs ( Table 3) . As in our investigation, DTC prevalence was markedly higher than for MMs. Concerning the IHC detection of DTCs it is important to realize that potential false positive results cannot be fully excluded, although we used strict morphological criteria to determine DTCs, that is, increased size and irregular shape of the nuclei, prominent nucleoli and scarce cytoplasm with irregular (pronounced intense or pale) staining. 30 These might be due to resident CK-positive interstitial reticulum cells and could hamper proper analysis. 40 In addition, heterotopic anti-CK-reactive salivary gland tissue might be present in cervical LNs especially of the upper cervical region based on the close relation of developing lymphoid and salivary tissue in the embryo. 45 To definitely prove the malignant origin of marker-positive DTCs, genetic analysis would be required, which is technically barely possible in sectioned single cells within FFPE-tissues.
However, the best indication that marker-positive DTCs were indeed cancer-related, came from their meticulous topographical analysis. This was enabled by mapping each LN according to the AAHNS-scheme. 24 Strikingly, we found a clear accumulation of DTC/MM-positive LNs located most proximate to the primary tumor. Further, if more than one LN was affected, the distribution pattern was not random but was dependent on the lateralization of the primary tumor. Furthermore, with very few exceptions the lymphatic dissemination pattern followed the routes of established metastasis in HNSCC 37 : If LNs in contralateral levels or more distant ipsilateral levels contained DTCs, LNs in levels more proximal to the primary tumor were also affected. Skipping of one or more levels was rarely observed.
DTCs are regarded as potential metastatic precursors cells, mainly because of their often reported strong prognostic impact. 16, 46 Further support for their malignant nature came from single cell analyses of marker positive DTCs isolated from specifically prepared LN-samples, which disclosed their malignant genotype 47, 48 and from report of a tumorigenic cell line generated from a LN DTC in esophageal cancer. 49 However, in HNSCC the prognostic significance of DTCs has so far not been established by previous investigations (Table  3) . This triggered us to correlate our DTC data with the clinical follow-up, but we could not observe any prognostic significance (Fig. 3) . This result did not marginalize our DTC findings. Rather two important conclusions can be drawn from our data: (i) early lymphatic tumor cell dissemination does not indicate clinical fast progressing systemic disease in HNSCC, since metastatic relapse did not occur in our patient cohort within the observation period; (ii) elective neck dissection should be performed even in early stage HNSCC to remove LNs containing DTCs to reduce local relapse and increase OS. Hence, our DTC findings support the data of several recent randomized clinical trials comparing the prognostic impact of elective neck dissection versus observation in cN0-HNSCC-patients, similar to our cohort. Because the incidence of delayed LN-metastases was up to six times higher in the observation groups, the DFS was significantly shorter. 7 Despite salvage neck dissection and adjuvant radiotherapy the OS rate was lower in the observation group, too. 50 There is still little evidence about the role of LN-DTCs in the further course of the disease, but we think that the study supports the clinical practice of elective neck dissections. This is supported by the fact that neck recurrence was not observed in our patient cohort during the 71 month follow-up period. Contralateral findings are rare, and therefore our data do not support comprehensive contralateral neck dissections. Our work also provides new insights into the dissemination of tumor cells through the lymphatic system in HNSCC, which seems to take place already at early tumor stages. Nonetheless, the functional role of these early disseminated cells and their true metastatic potential can only be addressed by molecular analyses and comparison with established metastases.
